GlassScriptPhysician profile
Roberto Miranda-Quesda
NPI 1952071854
$9,432.22
in general payments reported to CMS, 2019-2025
27 companies · $3,202 in 2025
The $3,202 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $698 · 2023: $3,279 · 2024: $2,038 · 2025: $3,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,494 · Travel and Lodging: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,493.93 |
| Travel and Lodging | $1,025.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,564.16 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Livanova USA, INC. | $1,521.69 | 2023-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $1,355.01 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $1,240.69 | 2022-2025 | |
| Corium, LLC | $861.80 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $510.97 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $350.55 | 2023-2024 | Jornay Pm |
| Sumitomo Pharma America, INC. | $339.23 | 2023-2024 | Aptiom |
| Collegium Pharmaceutical, INC. | $307.17 | 2025 | Jornay Pm |
| Catalyst Pharmaceuticals, INC. | $298.56 | 2023-2025 | Fycompa |
| Eisai INC. | $145.50 | 2022-2023 | |
| Noven Therapeutics, LLC | $145.45 | 2024-2025 | Xelstrym |
| Acadia Pharmaceuticals INC | $135.38 | 2024-2025 | Daybue |
| Sunovion Pharmaceuticals INC. | $118.09 | 2021-2022 | |
| Otter Pharmaceuticals, LLC | $87.45 | 2025 | Sympazan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aucta Pharmaceuticals, INC. | $72.28 | 2024-2025 | Motpoly Xr |
| Immedica Pharma US, INC. | $62.54 | 2023 | |
| Tris Pharma INC | $60.74 | 2022-2025 | Dyanavel Xr |
| Zogenix INC. | $56.95 | 2021 | |
| Sk Life Science, INC. | $42.85 | 2024 | |
| Upsher-Smith Laboratories LLC | $28.76 | 2025 | |
| Ns Pharma, INC. | $27.48 | 2025 | Viltepso |
| Allergan, INC. | $26.15 | 2022 | |
| Aquestive Therapeutics, INC. | $24.16 | 2025 | |
| Biogen, INC. | $20.62 | 2023 | Spinraza |
| Vertical Pharmaceuticals, LLC | $15.39 | 2025 | Relexxii |
| Phadia US INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Miranda-Quesda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.